Amedisys(AMED)
搜索文档
AMED Q3 Earnings and Revenues Miss, Margins Dip, Stock Falls
ZACKS· 2024-11-11 22:40
Amedisys, Inc. (AMED) reported adjusted earnings per share (EPS) of $1.00 in the third quarter of 2024, up 2% year over year. However, the metric missed the Zacks Consensus Estimate by 12.3%.The quarter’s adjustments include certain merger-related expenses and other (income)/expenses, net.GAAP EPS was 51 cents compared with 79 cents in the corresponding period of 2023.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.Following the earnings announcement, AMED’s shares lost 0.1% to reach ...
Amedisys(AMED) - 2024 Q3 - Quarterly Report
2024-11-07 21:00
收入与利润情况 - 2024年第三季度合并净服务收入增加3200万美元但运营收入减少1200万美元受多种因素影响包括并购相关费用增加等[112] - 2024年第三季度净收入为1650万美元低于2023年同期的2560万美元[113] - 2024年前九个月净服务收入为1750.3百万美元2023年同期为1665.6百万美元[138] - 2024年前九个月运营收入为114.2百万美元较2023年减少8百万美元[138] 业务板块收入与运营情况 - 2024年公司约70%的合并净服务收入来自医疗保险2023年同期约73%[102] - 家庭健康板块2024年净服务收入3.721亿美元较2023年增加2100万美元[118] - 家庭健康板块2024年运营收入5450万美元较2023年减少200万美元[118] - 家庭健康板块2024年医保收入同比下降3%非医保收入同比增长20%[118] - 家庭健康板块2024年总入院人数109856较2023年增加[118] - 临终关怀板块2024年运营收入4970万美元较2023年增加300万美元[125] - 高敏锐度护理板块2024年净服务收入770万美元较2023年增加300万美元[131] - 高敏锐度护理板块2024年总入院人数873较2023年增长51%[131] - 家庭健康板块2024年非医保收入同比增长20%医保收入同比降低1%[140] - 家庭健康板块2024年总入院人数较2023年增长12%总业务量增长9%[140] - 家庭健康板块2024年总运营收入较2023年增长69百万美元[142] - 家庭健康板块2024年服务总成本同比增长9%[143] - 临终关怀板块2024年运营收入较2023年增长4百万美元[145] - 临终关怀板块2024年净服务收入较2023年增长20百万美元[146] - 临终关怀板块2024年服务成本同比增长4%[149] - 高敏锐度护理部门2024年第三季度净服务收入为2390万美元2023年同期为1310万美元[154] - 高敏锐度护理部门2024年第三季度运营亏损1550万美元2023年同期为1970万美元[154] - 高敏锐度护理部门总入院人数增长42%[154] 企业并购与业务出售 - 2023年6月26日公司与UnitedHealth Group等达成合并协议但合并受多种条件限制且存在不确定性[105] - 2024年6月28日公司与UnitedHealth Group等达成协议出售部分护理中心但交易完成取决于合并等条件[106] - 2023年5月3日与Option Care Health的合并协议于6月26日终止公司支付1.06亿美元终止费[107] - 2023年3月31日出售个人护理业务获得净收益4780万美元并确认220万美元损失[108] - 个人护理业务于2023年3月31日出售[151] 政府支付预期影响 - CMS预计2025年为临终关怀服务的支付将增加2.9%公司预计受此影响符合该比例[109] - CMS预计2025年为家庭医疗服务的支付将增加0.5%公司预计受此影响符合该比例[111] 利息收入情况 - 2024年三季度利息收入为2.0美元2023年同期为1.3美元[116] 企业费用情况 - 公司2024年企业一般和管理费用6630万美元较2023年增加1300万美元[136] - 公司2024年运营总支出6740万美元较2023年增加1300万美元[136] - 公司企业一般及行政费用同比增加2300万美元[159] 现金流与资本支出情况 - 2024年9个月期间经营现金流较2023年同期增加7450万美元[161] - 2024年9个月期间资本支出和技术资产投资为610万美元2023年同期为1060万美元[164] - 2024年资本支出和技术资产投资预计约为800万美元[164] 企业资金与信贷情况 - 截至2024年9月30日公司有2.455亿美元现金及现金等价物[165] - 截至2024年9月30日公司在5.5亿美元循环信贷额度下有5.112亿美元可用额度[165] - 公司预计有足够流动性满足未来12个月及以后的运营资本和偿债需求[165] - 公司信贷协议初始本金总额最高达10亿美元包括5.5亿美元循环信贷和最高4.5亿美元定期贷款[170] - 2024年9月30日公司5.5亿美元循环信贷未偿借款为0 2023年9月30日也为0[170] - 2024年9月30日止的三及九个月公司修订定期贷款加权平均利率为7.2% 2023年同期分别为7.1%和6.6%[170] - 2024年9月30日公司5.5亿美元循环信贷可用额度为5.112亿美元[170] 外部因素影响 - 公司运营受通胀影响尤其是人力成本通胀预计2024年持续受影响[171] - 截至2024年9月30日通胀影响已被部分缓解[171] - 公司面临利率波动带来的市场风险截至2024年9月30日受利率波动影响的未偿债务总额为3.55亿美元[173] - 利率每变动1.0%假设公司不偿还本金每年利息费用将变动约360万美元[173]
Amedisys (AMED) Reports Q3 Earnings: What Key Metrics Have to Say
ZACKS· 2024-11-07 11:30
For the quarter ended September 2024, Amedisys (AMED) reported revenue of $587.67 million, up 5.7% over the same period last year. EPS came in at $1.00, compared to $0.98 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $588.13 million, representing a surprise of -0.08%. The company delivered an EPS surprise of -12.28%, with the consensus EPS estimate being $1.14.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and ho ...
Amedisys (AMED) Q3 Earnings and Revenues Lag Estimates
ZACKS· 2024-11-07 09:11
Amedisys (AMED) came out with quarterly earnings of $1 per share, missing the Zacks Consensus Estimate of $1.14 per share. This compares to earnings of $0.98 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -12.28%. A quarter ago, it was expected that this home health care and hospice services provider would post earnings of $1.22 per share when it actually produced earnings of $1.32, delivering a surprise of 8.20%.Over the las ...
Amedisys(AMED) - 2024 Q3 - Quarterly Results
2024-11-07 05:30
Exhibit 99.1 AMEDISYS REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS BATON ROUGE, Louisiana (November 6, 2024) — Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three and ninemonth periods ended September 30, 2024. Three-Month Periods Ended September 30, 2024 and 2023 • Net service revenue increased $31.5 million to $587.7 million compared to $556.2 million in 2023. • Net income attributable to Amedisys, Inc. of $16.9 million, which is inclusive of merger-related expenses totaling $ ...
Amedisys Reports Third Quarter 2024 Financial Results
GlobeNewswire News Room· 2024-11-07 05:30
BATON ROUGE, La., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three and nine-month periods ended September 30, 2024. Three-Month Periods Ended September 30, 2024 and 2023 Net service revenue increased $31.5 million to $587.7 million compared to $556.2 million in 2023.Net income attributable to Amedisys, Inc. of $16.9 million, which is inclusive of merger-related expenses totaling $16.7 million ($16.7 million, net of tax) compared to net incom ...
Will Amedisys (AMED) Beat Estimates Again in Its Next Earnings Report?
ZACKS· 2024-10-17 01:15
If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Amedisys (AMED) . This company, which is in the Zacks Medical - Outpatient and Home Healthcare industry, shows potential for another earnings beat.This home health care and hospice services provider has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise f ...
AMED vs. CHE: Which Stock Is the Better Value Option?
ZACKS· 2024-10-17 00:45
Investors interested in stocks from the Medical - Outpatient and Home Healthcare sector have probably already heard of Amedisys (AMED) and Chemed (CHE) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The proven Zacks Rank emphasizes companies with positive estimate revision ...
Amedisys (AMED) Moves to Buy: Rationale Behind the Upgrade
ZACKS· 2024-10-01 01:00
Amedisys (AMED) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Individual investors ...
AMED or CHE: Which Is the Better Value Stock Right Now?
ZACKS· 2024-10-01 00:46
Investors interested in Medical - Outpatient and Home Healthcare stocks are likely familiar with Amedisys (AMED) and Chemed (CHE) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our Style Scores highlight companie ...